Annual Bleeding Rate Reduced to 0.53 Episodes Over 97 Weeks
No Increased Bleeding Risk Linked to Activities Such as Soccer and Judo

Hemlibra (ingredient name: emicizumab), a treatment for hemophilia A developed by JW Pharmaceutical, was found to maintain a low risk of bleeding in pediatric and adolescent patients even during physical activity.

JW Pharmaceutical Hemlibra Proven to Suppress Bleeding During Physical Activity in Pediatric Hemophilia Patients View original image

JW Pharmaceutical announced on April 6 that the results of a study administering Hemlibra to 46 Japanese pediatric and adolescent patients with hemophilia A were published in the international journal "TH Open."


Hemlibra is a therapy that mimics the mechanism of coagulation factor VIII. It can be used regardless of antibody status and is administered as a subcutaneous injection once every four weeks.


The study was conducted over approximately 97 weeks at 50 medical institutions in Japan. The research team analyzed changes in physical activity, bleeding episodes, safety, and quality of life after applying Hemlibra prophylactic therapy.


According to the analysis, before receiving Hemlibra, patients experienced an average of 1.5 to 2.0 bleeding episodes over the previous 12 or 24 weeks. After switching to Hemlibra, the median annual bleeding rate (ABR) decreased to 0.53 episodes.


During the study period, a total of 172 physical activities were recorded. More than 25 types of activities were identified, including moderate- and high-risk activities such as soccer and judo. Only one case of traumatic bleeding was reported, and no significant association was found between activity intensity and bleeding.


The quality of life indicators also improved. In a caregiver survey, 43.8% reported an increase in their child’s activity levels, while 56.3% noted reduced anxiety about bleeding. In terms of safety, no major adverse reactions were identified. In particular, there were no reports of intracranial bleeding or thromboembolism.



A JW Pharmaceutical representative stated, "This study is significant in that it demonstrates pediatric and adolescent hemophilia A patients who received Hemlibra prophylactic therapy can participate in various physical activities with a low risk of bleeding. We will continue to share information that can help improve treatment conditions for patients, based on evidence accumulated in real-world clinical settings."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing